JP2014503178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503178A5 JP2014503178A5 JP2013532287A JP2013532287A JP2014503178A5 JP 2014503178 A5 JP2014503178 A5 JP 2014503178A5 JP 2013532287 A JP2013532287 A JP 2013532287A JP 2013532287 A JP2013532287 A JP 2013532287A JP 2014503178 A5 JP2014503178 A5 JP 2014503178A5
- Authority
- JP
- Japan
- Prior art keywords
- tau
- antibody
- seq
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 83
- 108010026424 tau Proteins Proteins 0.000 claims description 83
- 239000012634 fragment Substances 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 20
- 208000034799 Tauopathies Diseases 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 230000000626 neurodegenerative effect Effects 0.000 claims description 17
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 7
- 206010034010 Parkinsonism Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000007387 gliosis Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 210000002241 neurite Anatomy 0.000 claims description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 230000002739 subcortical effect Effects 0.000 claims description 4
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims description 4
- 208000004434 Calcinosis Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 208000024571 Pick disease Diseases 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 102000057063 human MAPT Human genes 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000012634 optical imaging Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39175110P | 2010-10-11 | 2010-10-11 | |
| EP10013494.9 | 2010-10-11 | ||
| US61/391,751 | 2010-10-11 | ||
| EP10013494 | 2010-10-11 | ||
| PCT/IB2011/002786 WO2012049570A1 (en) | 2010-10-11 | 2011-10-11 | Human anti-tau antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016016975A Division JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503178A JP2014503178A (ja) | 2014-02-13 |
| JP2014503178A5 true JP2014503178A5 (enExample) | 2014-10-16 |
Family
ID=43602869
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532287A Pending JP2014503178A (ja) | 2010-10-11 | 2011-10-11 | ヒト抗タウ抗体 |
| JP2016016975A Expired - Fee Related JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016016975A Expired - Fee Related JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20130295021A1 (enExample) |
| EP (1) | EP2627672B1 (enExample) |
| JP (2) | JP2014503178A (enExample) |
| CN (1) | CN103339146B (enExample) |
| AU (1) | AU2011315181B2 (enExample) |
| BR (1) | BR112013008765B8 (enExample) |
| CA (1) | CA2813493C (enExample) |
| CY (1) | CY1120951T1 (enExample) |
| DK (1) | DK2627672T3 (enExample) |
| EA (1) | EA031698B1 (enExample) |
| ES (1) | ES2686550T3 (enExample) |
| HR (1) | HRP20181320T8 (enExample) |
| IL (1) | IL225670B (enExample) |
| LT (1) | LT2627672T (enExample) |
| MX (1) | MX345092B (enExample) |
| NZ (1) | NZ609984A (enExample) |
| PL (1) | PL2627672T3 (enExample) |
| PT (1) | PT2627672T (enExample) |
| SG (1) | SG189174A1 (enExample) |
| SI (1) | SI2627672T1 (enExample) |
| TR (1) | TR201812636T4 (enExample) |
| WO (1) | WO2012049570A1 (enExample) |
| ZA (1) | ZA201303175B (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| CA2859665C (en) | 2011-12-20 | 2024-05-21 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| EP2870176A4 (en) * | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| EP2885010B1 (en) * | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Methods of treating a tauopathy |
| US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| JP6284548B2 (ja) * | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ヒト抗タウ抗体 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| MX374811B (es) * | 2013-03-15 | 2025-03-06 | Ac Immune Sa | Anticuerpos anti-tau y métodos de uso. |
| SMT202000401T1 (it) * | 2013-06-10 | 2020-11-10 | Ipierian Inc | Metodi di trattamento di una taupatia |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| BR112016010454A2 (pt) * | 2013-11-27 | 2017-12-05 | Ipierian Inc | métodos para tratar uma taupatia |
| CR20160270A (es) | 2013-12-20 | 2016-09-05 | Hoffmann La Roche | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽，抗Tau抗体，及其使用方法 |
| CA2952741A1 (en) * | 2014-06-26 | 2015-12-30 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| EP3174898A2 (en) | 2014-07-29 | 2017-06-07 | Neurimmune Holding AG | Human-derived anti-huntingtin (htt) antibodies and uses thereof |
| BR112017006419A2 (pt) * | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| CA3001724A1 (en) * | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
| EP3221349B1 (en) * | 2014-11-19 | 2020-11-04 | Axon Neuroscience SE | Humanized tau antibodies in alzheimer's disease |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US10202444B2 (en) | 2015-02-24 | 2019-02-12 | Rpeptide, Llc | Anti-tau antibodies |
| AR103713A1 (es) * | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| WO2016164530A1 (en) * | 2015-04-07 | 2016-10-13 | University Of Maryland, College Park | Compositions and methods for high throughput protein sequencing |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| ES2809728T3 (es) | 2015-06-24 | 2021-03-05 | Hoffmann La Roche | Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| SG10202010735PA (en) * | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CN105388302A (zh) * | 2015-12-22 | 2016-03-09 | 中国医学科学院输血研究所 | 一种人免疫球蛋白制品中Tau蛋白抗体含量的检测方法 |
| PL3430397T3 (pl) | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2018015022A (es) | 2016-06-07 | 2019-08-14 | Biogen Int Neuroscience Gmbh | Métodos para el tratamiento de la enfermedad de alzheimer. |
| JP7029415B2 (ja) | 2016-07-12 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 過リン酸化タウに特異的な抗体およびその使用方法 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| US10570196B2 (en) * | 2016-07-20 | 2020-02-25 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| MA45715A (fr) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | Anticorps anti-hspa5 (grp78) et leurs utilisations |
| JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| EP3509622A4 (en) | 2016-09-08 | 2020-06-17 | Regenerative Research Foundation | BIFUNCTIONAL ANTI-TAU POLYPEPTIDES AND USE THEREOF |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| EP3551220B1 (en) | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| TWI771389B (zh) | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| CN117205311A (zh) | 2017-03-28 | 2023-12-12 | 基因泰克公司 | 治疗神经退行性疾病的方法 |
| CA3056517A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| EP3602046A1 (en) * | 2017-03-28 | 2020-02-05 | Janssen Vaccines & Prevention B.V. | Methods for detection of tau protein aggregation modulating compounds |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| EA202090063A1 (ru) * | 2017-06-16 | 2020-04-03 | Бристоль-Мейерз Сквибб Компани | Композиции и способы для лечения таупатий |
| MD3672631T3 (ro) | 2017-08-22 | 2023-09-30 | Biogen Ma Inc | Compoziții farmaceutice conținând anticorpi anti-beta amiloidici |
| GEAP202215303A (en) | 2017-10-02 | 2022-04-11 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| AU2018380765A1 (en) * | 2017-12-04 | 2020-06-11 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| WO2019113711A1 (en) | 2017-12-14 | 2019-06-20 | University Of Ottawa | Exosome packaging and targeted autophagy |
| US12398201B2 (en) | 2018-02-19 | 2025-08-26 | New York University | Tau single domain antibodies |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| TW201946654A (zh) * | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | 抗ＰＨＦ－Ｔａｕ抗體及其用途 |
| CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| EP3829634A1 (en) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
| MA54070A (fr) | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI859197B (zh) | 2019-03-03 | 2024-10-21 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| EP3976793A4 (en) * | 2019-05-27 | 2023-06-21 | The University of British Columbia | CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES AGAINST IT AND METHODS RELATED THERETO |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| TWI832183B (zh) | 2019-08-06 | 2024-02-11 | 香港商新旭生技股份有限公司 | 結合至病理性tau種類之抗體及其用途 |
| WO2021055973A2 (en) * | 2019-09-20 | 2021-03-25 | Navi Bio-Therapeutics, Inc. | Personalized cancer immunotherapy |
| CN116723856A (zh) | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
| US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| CN118871989A (zh) | 2022-03-14 | 2024-10-29 | 基因泰克公司 | 基于语音分析来预测神经退行性疾病 |
| KR20250026248A (ko) | 2022-06-21 | 2025-02-25 | 제넨테크, 인크. | 음성 분석에 기초한 알츠하이머병(ad)의 종단적 진행 검출 |
| MA71622A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Domaines de liaison à l'antigène cd98hc et leurs utilisations |
| CN119497721A (zh) | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
| CN117106081B (zh) * | 2023-09-28 | 2024-05-07 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| CN117969825A (zh) * | 2024-02-18 | 2024-05-03 | 上海信利健康管理有限公司 | 一种人尿液中的磷酸化Tau蛋白的胶体金免疫层析检测卡及其制备方法 |
| CN120174021A (zh) * | 2024-03-08 | 2025-06-20 | 百奥赛图(北京)医药科技股份有限公司 | 一种tau基因修饰的非人动物 |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026102093A1 (en) | 2024-11-07 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119661705B (zh) * | 2024-11-22 | 2025-06-24 | 上海伯杰医疗科技股份有限公司 | 一种抗p-Tau217蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ATE154642T1 (de) * | 1991-10-25 | 1997-07-15 | Innogenetics Nv | Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau. |
| JPH07503132A (ja) * | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| CA2149326C (en) | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Fully impaired consensus kozak sequences for mammalian expression |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| ATE335007T1 (de) | 1993-12-21 | 2006-08-15 | Innogenetics Nv | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
| CA2195672A1 (en) | 1994-07-29 | 1996-02-15 | Eugeen Vanmechelen | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US20040110938A1 (en) | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| CA2456121A1 (en) * | 2001-08-03 | 2003-02-20 | Medical Research Council | Intracellular antibodies |
| EP1418807B8 (en) | 2001-08-24 | 2008-04-23 | Universität Zürich | A method of inducing the formation of neurofibrillary tangles in transgenic animals |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| DE60334460D1 (de) | 2002-08-14 | 2010-11-18 | Mitsubishi Chem Medience Corp | Antikörper spezifisch für das tau-protein des zentralen nervensystems |
| WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| HUE033325T2 (en) * | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| JP2012502884A (ja) * | 2008-09-16 | 2012-02-02 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼ阻害剤およびその使用 |
| EP4218794A3 (en) * | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| WO2012045882A2 (en) | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| US20120323214A1 (en) | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| JP6284548B2 (ja) | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ヒト抗タウ抗体 |
-
2011
- 2011-10-11 LT LTEP11797115.0T patent/LT2627672T/lt unknown
- 2011-10-11 SI SI201131553T patent/SI2627672T1/sl unknown
- 2011-10-11 US US13/878,839 patent/US20130295021A1/en not_active Abandoned
- 2011-10-11 JP JP2013532287A patent/JP2014503178A/ja active Pending
- 2011-10-11 TR TR2018/12636T patent/TR201812636T4/tr unknown
- 2011-10-11 WO PCT/IB2011/002786 patent/WO2012049570A1/en not_active Ceased
- 2011-10-11 AU AU2011315181A patent/AU2011315181B2/en not_active Ceased
- 2011-10-11 BR BR112013008765A patent/BR112013008765B8/pt not_active IP Right Cessation
- 2011-10-11 SG SG2013023775A patent/SG189174A1/en unknown
- 2011-10-11 ES ES11797115.0T patent/ES2686550T3/es active Active
- 2011-10-11 CN CN201180048980.7A patent/CN103339146B/zh not_active Expired - Fee Related
- 2011-10-11 US US13/271,118 patent/US8940272B2/en active Active
- 2011-10-11 NZ NZ609984A patent/NZ609984A/en not_active IP Right Cessation
- 2011-10-11 MX MX2013003879A patent/MX345092B/es active IP Right Grant
- 2011-10-11 EP EP11797115.0A patent/EP2627672B1/en active Active
- 2011-10-11 DK DK11797115.0T patent/DK2627672T3/en active
- 2011-10-11 EA EA201390453A patent/EA031698B1/ru unknown
- 2011-10-11 HR HRP20181320TT patent/HRP20181320T8/hr unknown
- 2011-10-11 PT PT11797115T patent/PT2627672T/pt unknown
- 2011-10-11 PL PL11797115T patent/PL2627672T3/pl unknown
- 2011-10-11 CA CA2813493A patent/CA2813493C/en active Active
-
2013
- 2013-04-10 IL IL225670A patent/IL225670B/en active IP Right Grant
- 2013-04-30 ZA ZA2013/03175A patent/ZA201303175B/en unknown
-
2014
- 2014-11-04 US US14/532,531 patent/US9605059B2/en not_active Expired - Fee Related
-
2016
- 2016-02-01 JP JP2016016975A patent/JP6300842B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-08 US US15/427,733 patent/US20180002409A1/en not_active Abandoned
-
2018
- 2018-09-12 US US16/128,978 patent/US20190233506A1/en not_active Abandoned
- 2018-11-01 CY CY181101135T patent/CY1120951T1/el unknown
-
2020
- 2020-09-17 US US17/023,814 patent/US20210238265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505665A5 (enExample) | ||
| JP2017205118A5 (enExample) | ||
| JP7676556B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 | |
| JP2012512634A5 (enExample) | ||
| DK2732289T3 (en) | ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS | |
| US11022618B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP2018534236A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| JP2017522886A5 (enExample) | ||
| JP2014528695A5 (enExample) | ||
| JP2017532288A5 (enExample) | ||
| HRP20150831T1 (hr) | Humana anti-alfa- sinuklein auto-protutijela | |
| JP2014502141A5 (enExample) | ||
| CN104662423A (zh) | 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ | |
| CN116348769A (zh) | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 | |
| KR20160145540A (ko) | 인산화 타우 단백질로 향하는 낙타과 동물의 단일-도메인 항체 | |
| FI3334761T3 (fi) | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa | |
| JP2018516849A5 (enExample) | ||
| US20200278358A1 (en) | Method of distinguishing between different neurodegenerative diseases | |
| US20220260593A1 (en) | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia | |
| JP7197494B2 (ja) | 抗Ｔａｕナノボディ | |
| EP3657175A1 (en) | Diagnostic set of reagents for detecting chronic pathologies of cerebral ischemic origin | |
| US11293925B2 (en) | Identifying amyloidogenic proteins and amyloidogenic risk | |
| US10570195B2 (en) | Conformation-independent antibodies against neurotoxic tau proteins | |
| US20250264482A1 (en) | Stereotypic bcr clonotypes in alzheimer's disease patients and use thereof |